Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Positron Emission Tomography Study in Healthy Male Subjects to Investigate Brain DAT and SERT Occupancy, Pharmacokinetics and Safety of Single Oral Doses ofGSK1360707, Using 11C- PE2I and 11C-DASB as PET Ligands

NCT01153802 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01153802
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01153802 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Positron Emission Tomography Study in Healthy Male Subjects to Investigate Brain DAT and SERT Occupancy, Pharmacokinetics and Safety of Single Oral Doses ofGSK1360707, Using 11C- PE2I and 11C-DASB as PET Ligands
Lead sponsor
GlaxoSmithKline
Phase
Phase 1
Overall status
Completed
Start date
April 3, 2009
Completion date
October 12, 2009
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

depressive disorder